The Life Sciences Capital Markets team represented the underwriters in connection with Krystal Biotech’s approximately $125 million follow-on offering of its common stock. The offering consisted of 2,275,000 shares of Krystal’s common stock, which were sold to investors at a price of $55.00 per share. The underwriters have a 30-day option to purchase up to an additional 341,250 shares of common stock. Cowen and Company, LLC and Evercore Group L.L.C. acted as joint book-running managers.
Krystal is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases.
The Goodwin team was led by Peter Rodas with assistance from Elizabeth Mulkey and Lily Xu.
For additional details on the offering, please read Krystal’s press release.